Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Net Income (2016 - 2020)

Historic Net Income for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2020 value amounting to -$19.9 million.

  • Syndax Pharmaceuticals' Net Income fell 3980.99% to -$19.9 million in Q4 2020 from the same period last year, while for Sep 2021 it was -$19.9 million, marking a year-over-year increase of 6980.29%. This contributed to the annual value of -$318.5 million for FY2024, which is 5239.83% down from last year.
  • According to the latest figures from Q4 2020, Syndax Pharmaceuticals' Net Income is -$19.9 million, which was down 3980.99% from -$19.9 million recorded in Q3 2020.
  • Syndax Pharmaceuticals' 5-year Net Income high stood at -$8.4 million for Q2 2016, and its period low was -$19.9 million during Q4 2020.
  • Over the past 5 years, Syndax Pharmaceuticals' median Net Income value was -$15.1 million (recorded in 2017), while the average stood at -$15.4 million.
  • In the last 5 years, Syndax Pharmaceuticals' Net Income tumbled by 14593.4% in 2016 and then surged by 2652.46% in 2019.
  • Over the past 5 years, Syndax Pharmaceuticals' Net Income (Quarter) stood at -$10.9 million in 2016, then crashed by 74.99% to -$19.0 million in 2017, then decreased by 1.61% to -$19.3 million in 2018, then increased by 26.52% to -$14.2 million in 2019, then tumbled by 39.81% to -$19.9 million in 2020.
  • Its last three reported values are -$19.9 million in Q4 2020, -$19.9 million for Q3 2020, and -$16.6 million during Q2 2020.